Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is -16170.91%.
Reported quarterly EBITDA margin; no daily interpolation.
Limited quarterly history available
EBITDA Margin needs at least three reported quarters before a meaningful chart is shown.
EBITDA MARGIN
-16170.91%
EBITDA MARGIN AVG TTM
N/A
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Kalaris Therapeutics Inc
Market Cap
$61.77M
EBITDA Margin
-16170.91%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$59.67M
EBITDA Margin
-89640.62%
TTM Avg
-44862.17%
3Y Avg
-44862.17%
5Y Avg
-44862.17%
Market Cap
$60.81M
EBITDA Margin
-270.28%
TTM Avg
-442.93%
3Y Avg
-1031.00%
5Y Avg
-861.19%
Market Cap
$63.23M
EBITDA Margin
-46.36%
TTM Avg
-44.45%
3Y Avg
-49.00%
5Y Avg
-37.18%
Market Cap
$64.09M
EBITDA Margin
-11538.23%
TTM Avg
-6406.80%
3Y Avg
-3544.47%
5Y Avg
-2835.62%
Market Cap
$59.71M
EBITDA Margin
-753.96%
TTM Avg
-753.96%
3Y Avg
-753.96%
5Y Avg
-753.96%
Market Cap
$64.39M
EBITDA Margin
-0.14%
TTM Avg
-3.20%
3Y Avg
-62.68%
5Y Avg
-125.61%
Market Cap
$59.56M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$58.79M
EBITDA Margin
-3226.05%
TTM Avg
-3226.05%
3Y Avg
-3226.05%
5Y Avg
-3226.05%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kalaris Therapeutics Inc (KLRS) | $61.77M | -16170.91% | N/A | N/A | N/A |
| Connect Biopharma Holdings Limited (CNTB)vs › | $59.67M | -89640.62% | -44862.17% | -44862.17% | -44862.17% |
| Adicet Bio, Inc. (ACET)vs › | $60.81M | -270.28% | -442.93% | -1031.00% | -861.19% |
| Alps Group Inc (ALPS)vs › | $63.23M | -46.36% | -44.45% | -49.00% | -37.18% |
| Pliant Therapeutics, Inc. (PLRX)vs › | $64.09M | -11538.23% | -6406.80% | -3544.47% | -2835.62% |
| Oncolytics Biotech Inc. (ONCY)vs › | $59.71M | -753.96% | -753.96% | -753.96% | -753.96% |
| Heron Therapeutics, Inc. (HRTX)vs › | $64.39M | -0.14% | -3.20% | -62.68% | -125.61% |
| PDS Biotechnology Corporation (PDSB)vs › | $59.56M | N/A | N/A | N/A | N/A |
| MiNK Therapeutics, Inc. (INKT)vs › | $58.79M | -3226.05% | -3226.05% | -3226.05% | -3226.05% |
| Fractyl Health, Inc. (GUTS)vs › | $58.50M | -99843.01% | -70984.01% | -70984.01% | -70984.01% |
Gross Margin
0.0%
EBITDA Margin
-16170.9%
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2019-03-31 | -1680.61% |
